Author:
Inokuchi Koiti,Kumagai Takashi,Matsuki Eri,Ohashi Kazuteru,Shinagawa Atsushi,Hatta Yoshihiro,Takeuchi Jin,Yoshida Chikashi,Wakita Hisashi,Kozai Yasuji,Shirasugi Yukari,Fujisawa Shin,Iwase Osamu,Yano Shingo,Okamoto Shinichiro,Oba Koji,Sakamoto Junichi,Sakamaki Hisashi
Publisher
Japanese Society for Lymphoreticular Tissue Research
Reference30 articles.
1. 1 Wong S, Witte ON: The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 22:247-306, 2004
2. 2 Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
3. 3 Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
4. 4 Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, et al.: Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 8:2167-2176, 2002
5. 5 Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006